1. Home
  2. MESO vs WABC Comparison

MESO vs WABC Comparison

Compare MESO & WABC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MESO
  • WABC
  • Stock Information
  • Founded
  • MESO 2004
  • WABC 1972
  • Country
  • MESO Australia
  • WABC United States
  • Employees
  • MESO N/A
  • WABC N/A
  • Industry
  • MESO Biotechnology: Biological Products (No Diagnostic Substances)
  • WABC Major Banks
  • Sector
  • MESO Health Care
  • WABC Finance
  • Exchange
  • MESO Nasdaq
  • WABC Nasdaq
  • Market Cap
  • MESO 1.4B
  • WABC 1.3B
  • IPO Year
  • MESO N/A
  • WABC N/A
  • Fundamental
  • Price
  • MESO $10.97
  • WABC $49.85
  • Analyst Decision
  • MESO Buy
  • WABC Hold
  • Analyst Count
  • MESO 4
  • WABC 3
  • Target Price
  • MESO $18.00
  • WABC $52.50
  • AVG Volume (30 Days)
  • MESO 156.4K
  • WABC 155.3K
  • Earning Date
  • MESO 02-26-2025
  • WABC 04-17-2025
  • Dividend Yield
  • MESO N/A
  • WABC 3.70%
  • EPS Growth
  • MESO N/A
  • WABC N/A
  • EPS
  • MESO N/A
  • WABC 4.99
  • Revenue
  • MESO $5,670,000.00
  • WABC $284,570,000.00
  • Revenue This Year
  • MESO $152.37
  • WABC N/A
  • Revenue Next Year
  • MESO $336.12
  • WABC N/A
  • P/E Ratio
  • MESO N/A
  • WABC $10.01
  • Revenue Growth
  • MESO N/A
  • WABC N/A
  • 52 Week Low
  • MESO $5.78
  • WABC $42.00
  • 52 Week High
  • MESO $22.00
  • WABC $59.97
  • Technical
  • Relative Strength Index (RSI)
  • MESO 44.34
  • WABC 59.46
  • Support Level
  • MESO $10.77
  • WABC $47.94
  • Resistance Level
  • MESO $11.61
  • WABC $50.28
  • Average True Range (ATR)
  • MESO 0.47
  • WABC 1.00
  • MACD
  • MESO 0.09
  • WABC 0.35
  • Stochastic Oscillator
  • MESO 27.68
  • WABC 90.23

About MESO Mesoblast Limited

Mesoblast Ltd is a biotechnology company. It uses its proprietary technology platform to develop and commercialize allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care and where inflammation plays a central role. The company's product candidates include; Ryoncil (remestemcel-L) for the treatment of steroid refractory acute graft versus host disease as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of cell technology platform for commercialization.

About WABC Westamerica Bancorporation

Westamerica Bancorp is based in San Rafael, California. Westamerica Bancorporation runs a regional community bank and has approximately $7.5 billion in assets. The banks' net revenue is generated by net interest income. Deposit service charges make up the noninterest income sources. The bank focuses mostly on commercial clients, such as smaller businesses. Its footprint encompasses central and northern California, extending north of San Francisco to Mendocino and Lake counties, south to Kern County in central California, and all the way east to Nevada County.

Share on Social Networks: